Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 10human papillomavirus vaccine, L1 type 16, 18 7olaparib 4niraparib 4Human Papillomavirus Recombinant Vaccine nonavalent 4Vaccines 3Saline Solution 3Papillomavirus Vaccines 3Medroxyprogesterone Acetate 3Carboplatin 3Bevacizumab 3pegylated granulocyte colony-stimulating factor 2liposomal doxorubicin 2fluciclovine F-18 2apatinib 2Sevoflurane 2Propofol 2Paclitaxel 2Aspirin 2semaglutide 1pegfilgrastim 1pazopanib 1palbociclib 1lenvatinib 1halofantrine 1ganirelix 1gadofosveset trisodium 1fosaprepitant 1follicle stimulating hormone, human, with HCG C-terminal peptide 1ferrous gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × LY 353381 × Gynecologic × Clear all
NCT00190697 2007-05-25

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Eli Lilly and Company

Phase 4 Completed
70 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡